Us Bancorp \De\ Uro Gen Pharma Ltd. Transaction History

Us Bancorp \De\

$71.8 Billion
Q1 2024

A detailed history of Us Bancorp \De\ transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Us Bancorp \De\ holds 134 shares of URGN stock, worth $2,196. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134

Previous 134 -0.0%

Holding current value

$2,196

Previous $2,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$10.87 - $15.93 $1,456 - $2,134	134 New	134 $2,000
Q1 2022 May 11, 2022	SELL	$5.92 - $9.73 $3,581 - $5,886	-605 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$9.03 - $19.13 $1,887 - $3,998	209 Added 52.78%	605 $6,000
Q3 2021 Nov 10, 2021	BUY	$14.31 - $18.39 $3,076 - $3,953	215 Added 118.78%	396 $6,000
Q2 2021 Aug 05, 2021	SELL	$15.2 - $20.94 $19,668 - $27,096	-1,294 Reduced 87.73%	181 $3,000

Q1 2021 Apr 28, 2021	SELL	$17.99 - $26.96 $7,825 - $11,727	-435 Reduced 22.77%	1,475 $29,000
Q4 2020 Feb 04, 2021	BUY	$17.54 - $25.43 $11,558 - $16,758	659 Added 52.68%	1,910 $35,000
Q3 2020 Nov 10, 2020	BUY	$18.81 - $26.42 $17,267 - $24,253	918 Added 275.68%	1,251 $24,000
Q2 2020 Aug 07, 2020	BUY	$16.5 - $29.7 $792 - $1,425	48 Added 16.84%	333 $9,000
Q1 2020 May 13, 2020	BUY	$13.68 - $34.6 $1,887 - $4,774	138 Added 93.88%	285 $5,000
Q4 2019 Feb 04, 2020	BUY	$21.11 - $34.86 $232 - $383	11 Added 8.09%	147 $5,000
Q4 2018 Feb 13, 2019	SELL	$38.35 - $50.39 $1,303 - $1,713	-34 Reduced 20.0%	136 $6,000
Q3 2018 Nov 01, 2018	BUY	$41.65 - $51.7 $7,080 - $8,789	170 New	170 $8,000

Others Institutions Holding URGN

# of Institutions

113

Shares Held

24M

Call Options Held

46.9K

Put Options Held

44.3K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $373M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account